Corcept Therapeutics Target Price

See Corcept Therapeutics's analyst price targets ($100) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$110.69

Average Target Price

$103.75

6.3% downside

8 analysts in the last 4 months

High: $165 | Low: $50

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-30	H.C. WainwrightSwayampakula Ramakanth	$165	49.1% upside
2026-07-29	Canaccord GenuityEdward Nash	$150	35.5% upside
2026-07-27	Wolfe Research	$50	54.8% downside
2026-06-02	H.C. WainwrightSwayampakula Ramakanth	$95	14.2% downside
2026-05-28	UBS	$135	22% upside
2026-05-13	UBS	$72	35% downside
2026-05-04	H.C. Wainwright	$75	32.2% downside
2026-05-01	Piper Sandler	$88	20.5% downside
2026-02-20	H.C. Wainwright	$67	39.5% downside
2026-01-23	Canaccord Genuity	$100	9.7% downside
2026-01-22	H.C. WainwrightSwayampakula Ramakanth	$105	5.1% downside
2026-01-02	H.C. WainwrightSwayampakula Ramakanth	$90	18.7% downside
2026-01-02	Canaccord GenuityEdward Nash	$99	10.6% downside
2025-12-31	Truist Financial	$50	54.8% downside
2025-12-31	Wolfe Research	$30	72.9% downside
2025-12-16	UBSAshwani Verma	$95	14.2% downside
2025-09-10	Canaccord Genuity	$140	26.5% upside
2025-05-06	Truist FinancialJoon Lee	$135	22% upside
2025-05-06	H.C. WainwrightSwayampakula Ramakanth	$145	31% upside
2024-10-18	H.C. WainwrightSwayampakula Ramakanth	$80	27.7% downside
2024-09-30	Truist FinancialJoon Lee	$76	31.3% downside
2024-08-15	Canaccord GenuityEdward Nash	$78	29.5% downside
2024-07-30	Piper SandlerDavid Amsellem	$38	65.7% downside
2024-07-30	H.C. WainwrightSwayampakula Ramakanth	$45	59.3% downside
2024-06-12	Canaccord GenuityEdward Nash	$38	65.7% downside
2024-06-10	Piper SandlerDavid Amsellem	$35	68.4% downside
2024-06-04	Truist FinancialJoon Lee	$65	41.3% downside
2024-05-02	H.C. WainwrightSwayampakula Ramakanth	$40	63.9% downside
2022-12-09	H.C. Wainwright	$30	72.9% downside
2022-08-04	H.C. Wainwright	$33	70.2% downside

Corcept Therapeutics (CORT) FAQ

Corcept Therapeutics posts a target price of $100. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $100 for CORT means covering analysts, on average, see the stock 6.3% downside of $110.69 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CORT's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Corcept Therapeutics's other metric pages and overview cover the third.

Judging Corcept Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $100 here, then scan peer and history charts to see if the gap is persistent.